LINDSEY GUILL: Open Payments
NPI 1639631328 · MADISON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$612 in 44 payments from 9 companies in 2025. Trend: 2023 $826 · 2024 $656 · 2025 $612
Food & beverage: $612
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 25 | $243 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $87 |
| Amgen Inc. | 5 | $87 |
| AstraZeneca Pharmaceuticals LP | 4 | $74 |
| Lilly USA, LLC | 2 | $42 |
| UCB, Inc. | 1 | $26 |
| Abbott Laboratories | 1 | $18 |
| Exact Sciences Corporation | 1 | $18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $16 |
Products named: XIFAXAN, Ozempic, AIRSUPRA, Rybelsus, OTEZLA, JARDIANCE, EVENITY, Bimzelx.
Industry payments across AL — which companies pay providers there.
